Open Evidence Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
16:00
Aug 12
Steve McLaughlin Founder, CEO, and Managing Partner, FT Partners Delphi Digital
Leading AI-first names are not bubbly.
Steve argues leading AI-first companies such as OpenAI, Anthropic, and Open Evidence are not in a bubble, unlike me-too AI vertical solutions without data or network-effect moats. He sees durable value in the quality AI-first names.
MED
16:17
Jan 19
Alex Rampell General Partner, a16z Apps Fund a16z
Open Evidence owns medical journal data.
Open Evidence has exclusive licensing to the New England Journal of Medicine and other medical journals, creating a proprietary data walled garden; with a ChatGPT-like interface it delivers evidence-based answers that general models cannot, making it valuable to doctors who use it weekly.
HIGH

About Open Evidence Investor Commentary

Across the available history and selected sources, Buzzberg tracks Open Evidence across 2 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Steve McLaughlin, Alex Rampell.